Bolt Biotherapeutics, Inc. (BOLT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Bolt Biotherapeutics reported revenue of $7.7M, up 0.1% from $7.7M the year before. Net income was -$33.4M (a -433.7% net margin), or -$17.85 per diluted share. Operating margin was -469.3%. Operating activities generated -$39.9M of cash, leaving -$39.9M of free cash flow. At fiscal year end, Bolt Biotherapeutics held $56.7M in total assets against $30.2M in total liabilities, including $11.7M of cash and equivalents.
Open the full interactive Bolt Biotherapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Bolt Biotherapeutics Key Stats
| Share Price | $4.28 |
|---|---|
| Market Cap | $7.2M |
| Revenue YoY Growth | +0.1% |
| 52-Week Range | $3.18 – $7.09 |
| Shares Outstanding | 1.7 million (basic, 2026 Q2) |
Bolt Biotherapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.3M | $5.7M | $7.9M | $7.7M | $7.7M |
| Operating Income | -$92.8M | -$90.3M | -$76.2M | -$73.0M | -$36.1M |
| Pre-Tax Income | -$98.6M | -$88.1M | -$69.2M | -$63.1M | -$33.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$98.6M | -$88.1M | -$69.2M | -$63.1M | -$33.4M |
| Diluted EPS | -$59.40 | -$47.20 | -$36.60 | -$33.00 | -$17.85 |
Bolt Biotherapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.2M | $2.5M | $26,000 | $5,000 |
| Net Income | -$7.1M | -$6.6M | -$7.2M | -$7.7M |
| Diluted EPS | -$3.72 | -$3.55 | -$4.31 | -$4.57 |
Bolt Biotherapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $27.4M | $9.2M | $10.8M | $7.2M | $11.7M |
| Current Assets | $189.2M | $172.7M | $105.7M | $50.8M | $30.3M |
| Total Assets | $307.7M | $227.8M | $159.8M | $99.6M | $56.7M |
| Current Liabilities | $21.3M | $23.1M | $20.5M | $15.9M | $8.4M |
| Total Liabilities | $57.6M | $56.3M | $47.0M | $42.4M | $30.2M |
| Shareholders' Equity | $250.1M | $171.5M | $112.7M | $57.2M | $26.5M |
Bolt Biotherapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$57.1M | -$76.5M | -$69.5M | -$61.3M | -$39.9M |
| Cash From Investing | -$232.2M | $57.9M | $71.0M | $57.6M | $44.3M |
| Cash From Financing | $311.1M | $503,000 | $253,000 | $108,000 | $19,000 |
| Free Cash Flow | -$59.4M | -$78.5M | -$69.7M | -$61.3M | -$39.9M |
Figures from Bolt Biotherapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Bolt Biotherapeutics financials page for every line item.
Bolt Biotherapeutics Company Profile
| Ticker | BOLT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Redwood City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001641281 |
Frequently Asked Questions
What was Bolt Biotherapeutics' revenue in fiscal 2025?
Bolt Biotherapeutics (BOLT) reported revenue of $7.7M for fiscal 2025.
What is Bolt Biotherapeutics' annual revenue history?
Bolt Biotherapeutics' annual revenue by fiscal year: 2021: $1.3M; 2022: $5.7M; 2023: $7.9M; 2024: $7.7M; 2025: $7.7M.
What was Bolt Biotherapeutics' net income in fiscal 2025?
Bolt Biotherapeutics reported net income of -$33.4M for fiscal 2025.
What was Bolt Biotherapeutics' earnings per share (EPS) in fiscal 2025?
Bolt Biotherapeutics' diluted EPS was -$17.85 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Bolt Biotherapeutics generate in fiscal 2025?
Bolt Biotherapeutics generated -$39.9M of free cash flow in fiscal 2025.
What was Bolt Biotherapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Bolt Biotherapeutics reported revenue of $5,000.
How many shares of Bolt Biotherapeutics are outstanding?
Bolt Biotherapeutics reported a weighted average of 1.7 million basic shares outstanding in 2026 Q2.
What is Bolt Biotherapeutics' market cap?
Based on its latest closing price, Bolt Biotherapeutics (BOLT) has a market capitalization of about $7.2M.
When does Bolt Biotherapeutics' fiscal year end?
Bolt Biotherapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Bolt Biotherapeutics headquartered?
Bolt Biotherapeutics lists its business address in Redwood City, California in its SEC filings.